The litigation, spearheaded by the Rosen Law Firm, alleges that ADMA Biologics artificially inflated its financial standing by employing channel stuffing tactics and failing to maintain necessary internal controls during the specified class period. According to the complaint, these practices rendered public statements regarding the company’s business operations materially false or misleading. When the underlying details surfaced, the lawsuit claims, shareholders sustained financial losses.

Those who held ADMA stock during this window may be eligible to participate in the litigation via a contingency fee arrangement, meaning participants incur no out-of-pocket costs. While the court has not yet certified a class, investors interested in serving as a representative party must file a motion with the court before the August 10 deadline. Investors are not required to serve as lead plaintiffs to remain eligible for potential future recovery, and they retain the right to select their own legal counsel.